COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples